Using patient data to fill in GLP-1 blind spots, with Phil Johnson

Patients
Interview with Phil Johnson at Pharma US 26

The GLP-1 market is huge and growing, and depending on how patients acquire and pay for their therapies, traditional data sources like claims data and EHR data don’t capture all these new patients.

Enter Evidation Health, a company built on delivering opt-in patient-generated data to healthcare stakeholders, including pharma companies.

At Reuters Pharma USA, Evidation Health Chief Commercial Officer Phil Johnson filled Editor in Chief Jonah Comstock in on the questions their customers are asking them about GLP-1s and how their unique data sources help them answer them.

In the full video below, learn about the new alliances between tech companies and GLP-1 manufacturers and the insights they’re uncovering together, from side effects to reimbursement to microdosing.


Market Access
12 questions with: Daniel Kohlstaedt

12 questions with: Daniel Kohlstaedt

Daniel Kohlstaedt, managing director of PurpleLeaf Strategy, with more than 18 years of experience in pharma, talks about his journey through the industry.